Metabolic pathway‐based subtyping reveals distinct microenvironmental states associated with diffuse large B‐cell lymphoma outcomes
Hematological Oncology · 2024
DOI: 10.1002/hon.3279 ↗At a glance
Journal article in Hematological Oncology, 2024. Written by Xiaohui Wang and 12 co-authors. Institution: National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine and Department of Lymphoma, Key Laboratory of Cancer Prevent…. Major MEDLINE topics: Lymphoma, Large B-Cell, Diffuse, Tumor Microenvironment, Metabolic Networks and Pathways. Cited 3 times so far (Crossref); 75 references. Funded by: Haihe Yingcai Project, Tianjin Key Medical Discipline Construction Project grant, Construction Project of Cancer Precision Diagnosis and Drug Treatment Technology.
Abstract (original language)
Diffuse large B‐cell lymphoma (DLBCL) is a biologically and clinically heterogeneous disease that requires personalized clinical treatment. Assigning patients to different risk categories and cytogenetic abnormality and genetic mutation groups has been widely applied for prognostic stratification of DLBCL. Increasing evidence has demonstrated that dysregulated metabolic processes contribute to the initiation and progression of DLBCL. Metabolic competition within the tumor microenvironment is also known to influence immune cell metabolism. However, metabolism‐ and immune‐related stratification has not been established. Here, 1660 genes involved in 84 metabolic pathways were selected and tested to establish metabolic clusters (MECs) of DLBCL. MECs established based on independent lymphoma datasets distinguished different survival outcomes. The CIBERSORT algorithm and EcoTyper were applied to quantify the relative abundance of immune cell types and identify variation in cell states for 13 lineages comprising the tumor micro environment among different MECs, respectively. Functional characterization showed that MECs were an indicator of the immune microenvironment and correlated with distinctive mutational characteristics and oncogenic signaling pathways. The novel immune‐related MECs exhibited promising clinical prognostic value and potential for informing DLBCL treatment decisions.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine and Department of Lymphoma, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospi…
ORCID profiles: Xianhuo Wang, Huilai Zhang
Funding
- Haihe Yingcai Project
- Tianjin Key Medical Discipline Construction Project grant
- Construction Project of Cancer Precision Diagnosis and Drug Treatment Technology
- Clinical Oncology Research Fund of CSCO
- Chinese Society of Clinical Oncology
- CACA-BeiGene Lymphoma Research Foundation
Cite
APA
Wang, X., Liu, H., Fei, Y., Song, Z., Meng, X., Yu, J., Liu, X., Li, L., Qiu, L., Qian, Z., Zhou, S., Wang, X., & Zhang, H. (2024). Metabolic pathway‐based subtyping reveals distinct microenvironmental states associated with diffuse large B‐cell lymphoma outcomes. Hematological Oncology. https://doi.org/10.1002/hon.3279
Vancouver
Wang X, Liu H, Fei Y, Song Z, Meng X, Yu J, et al. Metabolic pathway‐based subtyping reveals distinct microenvironmental states associated with diffuse large B‐cell lymphoma outcomes. Hematological Oncology. 2024. doi:10.1002/hon.3279
BibTeX
@article{Wang2024,
author = {Wang, Xiaohui and Liu, Hengqi and Fei, Yue and Song, Zheng and Meng, Xiangrui and Yu, Jingwei and Liu, Xia and Li, Lanfang and Qiu, Lihua and Qian, Zhengzi and Zhou, Shiyong and Wang, Xianhuo and Zhang, Huilai},
title = {Metabolic pathway‐based subtyping reveals distinct microenvironmental states associated with diffuse large B‐cell lymphoma outcomes},
journal = {Hematological Oncology},
year = {2024},
doi = {10.1002/hon.3279}
}
EUVIMED